TOPICAL ANESTHETIC FOR COSMETIC PROCEDURES NeuroMed7 is a topical, local anesthetic that can be used for a variety of procedures to improve patient comfort and satisfaction NeuroMed7 is a rapid onset of action OTC topical anesthetic that contains a combination of lidocaine HCl 4% with trans-dermal penetration/absorption enhancers It can be used as a topical anesthetic prior to a variety of medical procedures including: Injections Trigger point injections immunizations Myo-facial paralyzing injections (BOTOX therapy) Dermal fillers Minimally invasive procedures Venipuncture Can also be used for post procedural analgesia Can be used to mitigate pain, itch and burn related to cutaneous manifestations of a variety of conditions Safe and effective concentration of lidocaine HCl Rapid onset of action trans-dermal penetration/absorption enhanced OTC Affordable pricing

1. SAMBRIA
NeuroMed7™
“A Unique Approach In Topical Pain Management”

2. Our Mission
 Sambria Pharmaceuticals is a developer of
differentiated, highly effective topical pain relief
consumer healthcare products and medications.
 Our primary goals are to develop topical
formulations that provide clinicians, patients and
consumers with effective methods to mitigate
pain singularly or in conjunction with other
effective therapies in a regulatory compliant
manner.
 Assist healthcare clinicians in improving patient
comfort, satisfaction and overall doctor/patient
experience

3. Our Approach
 We have developed a proprietary topical pain relief
formula that combines the active ingredient,
lidocaine HCl with a blend of trans-dermal
penetration enhancers widely used in
pharmaceutical compounding.
 Clinical applications of our launch product include
topical anesthesia particularly for the
dermatological, aesthetic/cosmetic, pediatric,
podiatric and other specialties where rapid onset of
local anesthesia is medically warranted and desired
 Clinical studies being conducted around the globe
demonstrate the high degree of efficacy applying
transdermal delivery of topical lidocaine
applications in a safe manner when applied
responsibly.

4. Current and Potential
Applications
We are researching a broad range of current and potential future uses in
an effort to expand applications of this historically effective
anesthetic/analgesic.
 Dermatologic conditions
 Pre-and post-cosmetic/aesthetic procedure applications
 Minor surgical procedures
 IPL and LASER procedures
 Venipuncture
 Injections
 Immunizations
 Cutaneous allergy reactions
 Pediatric
 Neuropathic pain
 Musculoskeletal pain

5. NeuroMed7TM
 A topical anesthetic/analgesic cream that
combines the active ingredient lidocaine HCl 4%
with a proprietary blend of ingredients known in
pharmaceutical compounding to enhance
transdermal absorption of a variety of medicinal
therapies
 In a topical cream formulation, lidocaine HCl 4% is
applied externally as a local analgesic/anesthetic
medication.
 When used properly topical lidocaine
demonstrates a very low amount of lidocaine
entering the blood, limiting its systemic effects.

6. NeuroMed7TM
 It can be used to reduce pain locally when applied externally directly to
the skin.
 Typically will not cause profound, uncomfortable numbing of the skin
(lidocaine is known to cause numbing when applied by injection or to
mucous membranes),
 However, its action is known to desensitize the affected area where
applied.
 In combination with Sambria’s proprietary penetration enhancement
blend, NeuroMed7™ is demonstrating a rapid onset of action and
may serve physician needs for trans-dermal and sub-dermal
penetration
 It is free of counter irritant materials sometimes known to cause localized
skin irritation. On the contrary its uses include relief from pain caused by
skin irritations.
 This product is also free of topical acetaminophen or salicylates,
mitigating the risk of reactions in people with sensitivities to those
compounds.

7. Lidocaine HCL 4%
 The active ingredient in NeuroMed7™ falls under a class of
medication known as OTC Topical Analgesics and
Anesthetics. See US FDA Monograph CFR 21 348 OTC Topical
Anesthetics and Analgesics
 Medications in this class can be used for local pain relief
when applied externally.
 When applied topically, Lidocaine HCl 4% has analgesic and
anesthetic properties.
 In accordance with Federal Regulations, products in its
category can be used by children and adults 2 years of age
and older without prior consent of a licensed physician when
applied externally as an analgesic/anesthetic.

8. Product differentiators
 Rapid onset of action (typically 3 to 5 minutes)
 Proprietary blend that includes transdermal
penetration enhancers
 Safe concentration of topical anesthetic –
lidocaine HCl 4%
 Clinical use dose and patient retail size
packaging availability
 Cost effective – affordable price points
throughout the distribution chain; from distributor
to end user
 Co-branding

9. Facility Costs and Margins
 Sambria wholesales its product for $17.50 per tube.
 Tubes contain a blend of materials that include lidocaine HCl 4% in a
cream form. Tubes contain 2.2 ounces of cream per tube.
 Tubes are sold wholesale in cases of 48 units per case. The case
Wholesale Acquisition Cost (WAC) is $840 per case ($17.50 per tube)
 By special request, Sambria can package tubes in a 24 units case
box WAC is $445 per case ($18.54 per tube)
 The manufacturer suggested retail price (MSRP) is $34.95 per tube.
 When sold at the MSRP, Neuromed7™ has a nearly 100% markup.
 Sambria also produces one use packaging for clinical setting
applications – Wholesale Acquisition Cost (WAC) is $1.70 per
application dose packet (package includes 3 milliliters of product– 1
milliliter = 40 mgs lidocaine HCl – total application per package = 120
mgs)
 Clinic use individual packets are packaged in 100, 500, 1000 and
5000 unit boxes

10. Regulatory Compliance
 NeuroMed7™ is manufactured and marketed in
accordance with United States Food and Drug
Administration (US FDA or FDA) regulations.
 Regulation policies are governed by the US FDA
CFR 21 Monograph 348 OTC Topical Analgesic and
Anesthetics.
 Monograph policy specifically directs marketers of
medications in this class to list the uses “topical
analgesic”, “topical anesthetic”, “external
analgesic”, “external anesthetic” or “for the
temporary relief of pain” on its product packaging.
¹ Monograph CFR 21 348.50(a).1
 USA FDA NDC# 54723-175-22

11. Dermatological Safety and Efficacy
References Supporting the Use of OTC
4% Topical Lidocaine
 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923950/
 http://www.the-dermatologist.com/article/7737
 http://www.skinlaser.com/wp-
content/uploads/2011/07/2012AnestheticReviewDermSurg
-AlsterSobanko.pdf
 http://www.hospitalpharmacyeurope.com/featured-
articles/topical-anaesthetics-dermatology
 http://archderm.jamanetwork.com/article.aspx?articleid=
407139
 http://www.drugs.com/cdi/lidocaine-cream.html
 http://www.iacdworld.org/legal/lidocaine.htm
 http://otcsafety.org/en/treatments/topical-pain-relievers/
 http://www.webmd.com/drugs/mono-9170-LIDOCAINE+-
+TOPICAL.aspx?drugid=8532&drugname=Lidocaine+Top

12. NeuroMed7™

13. Thank You!